177Lu-DOTA-chCE7agl

**177Lu-DOTA-chCE7agl** is a radiolabeled antibody-drug conjugate specifically consisting of the aglycosylated chCE7 monoclonal antibody coupled to the chelator DOTA, which allows for the stable binding of the radionuclide lutetium-177 (^177Lu)[5][3][1]. The target of chCE7agl is **L1 cell adhesion molecule (L1-CAM)**, a protein overexpressed in several cancers, notably ovarian cancer. This drug delivers cytotoxic radiation directly to L1-CAM–positive tumor cells, enabling high and specific accumulation of radioactivity at the tumor site, resulting in significant tumor growth retardation and prolonged survival in animal models[3]. Studies have shown high stability of the radioimmunoconjugate and maintained immunoreactivity across varying numbers of DOTA moieties[1][5]. The primary indication investigated is **ovarian cancer**, and possibly other L1-CAM–expressing solid tumors[3][5].

Other names

177Lu-DOTA-chCE7agl^177Lu-DOTA-chCE7aglLutetium-177 DOTA-conjugated aglycosylated chCE7 monoclonal antibodyLutetium177 DOTA-conjugated aglycosylated chCE7 monoclonal antibodyLutetium 177 DOTA-conjugated aglycosylated chCE7 monoclonal antibody